MIPA - EIBIR’s first industry-sponsored study
In 2011 an action plan for a mutually beneficial collaboration between EIBIR and Bayer Pharma AG, one of EIBIR’s industrial partners was developed. This action plan subsequently formed the basis of an investigator initiated study entitled “Preoperative Breast MRI in Clinical Practice: Multicenter International Prospective Meta-Analysis of Individual Data (MIPA)”.
The study commenced in mid-2012 under the direction of EIBIR and Professor Francesco Sardanelli, University of Milan School of Medicine/IT and Director of EIBIR’s Joint Initiative EuroAIM, in collaboration with the European Society of Breast Imaging (EUSOBI) and with financial support from Bayer Pharma AG.
34 centres are involved. These are distributed across Europe, and also include sites in Australia and the US, with the central unit in Milan. The study aims to enrol 7000 women between the ages of 18-80 with newly diagnosed breast cancer. Subject enrolment began in 2013 and presentations, as well as the publication of survey results, are expected from 2014. As of 2018, the technical support for the study is provided by Kiwifarm.
EIBIR is delighted that Bayer Pharma AG has agreed to provide essential support for a study that will be crucial in increasing knowledge about the clinical use of contrast-enhanced breast MRI, and hopes that other Industry Panel members will do the same with similar projects in the future.